Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ANEXSIA 7.5/650 vs ACETAZOLAMIDE SODIUM
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Hydrocodone is a mu-opioid receptor agonist that inhibits ascending pain pathways and alters pain perception; acetaminophen inhibits cyclooxygenase (COX) enzymes, primarily in the CNS, reducing prostaglandin synthesis and fever.
Acetazolamide is a carbonic anhydrase inhibitor. It reversibly inhibits the enzyme carbonic anhydrase, which catalyzes the reversible hydration of carbon dioxide and dehydration of carbonic acid. This results in increased excretion of bicarbonate, sodium, potassium, and water in the urine, leading to metabolic acidosis. Additionally, it reduces aqueous humor secretion in the eye, lowering intraocular pressure, and can decrease cerebrospinal fluid production.
Management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate
Treatment of open-angle glaucoma and secondary glaucoma,Preoperative and perioperative reduction of intraocular pressure in acute angle-closure glaucoma,Treatment of edema due to congestive heart failure when other diuretics are ineffective,Adjunctive treatment of epilepsy (centrencephalic epilepsies, absence seizures),Prophylaxis and treatment of acute mountain sickness
1 tablet orally every 4 to 6 hours as needed; maximum 6 tablets per day.
Adult: 250-500 mg IV or IM every 12-24 hours; for edema, 250-375 mg IV once daily in morning. For glaucoma, 250-1000 mg IV or IM daily in divided doses.
Hydrocodone: Terminal half-life 3.8-7.2 hours (mean 5.6 h). Acetaminophen: 1.5-2.5 hours (therapeutic) but prolonged to >4 hours in overdose with hepatotoxicity risk.
10-15 hours (prolonged in renal impairment; cirrhosis increases t1/2 to 20-30 h).
Hydrocodone: CYP3A4 and CYP2D6; acetaminophen: primarily liver glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation (SULT1A1, SULT1A3), with minor CYP2E1 oxidation.
Acetazolamide is minimally metabolized in the liver, with the majority of the drug excreted unchanged in the urine. The primary metabolic pathway involves oxidation of the thiadiazole ring, but this is a minor route. The drug is not extensively biotransformed; hepatic metabolism accounts for less than 10% of elimination.
Hydrocodone: Renal elimination of metabolites (hydromorphone, norhydrocodone) and unchanged drug accounts for ~60-90% of clearance. Acetaminophen: ~85% of dose is excreted in urine as glucuronide and sulfate conjugates; 5-10% unchanged; 2-5% as mercapturate.
Primarily renal (90% unchanged via tubular secretion). <2% biliary/fecal.
Hydrocodone: ~36% bound to serum proteins. Acetaminophen: 10-25% bound (minimal binding).
70-90% (mainly carbonic anhydrase in RBCs; low affinity for albumin).
Hydrocodone: Vd ~3-5 L/kg (wide distribution). Acetaminophen: Vd ~0.9-1.0 L/kg (primarily body water).
Approximately 0.2-0.3 L/kg; mainly confined to extracellular fluid and highly perfused tissues.
Oral: Hydrocodone ~70-80% (variable first-pass). Acetaminophen ~63-89% (mean 75-80%).
Oral: ~90-100% (rapidly absorbed; food may delay). Intramuscular: not recommended (acidic p H).
Cr Cl <30 m L/min: contraindicated; Cr Cl 30-60 m L/min: maximum 3 tablets per day; given the hydrocodone component, avoid in severe renal impairment.
GFR 10-50 m L/min: administer every 12 hours. GFR <10 m L/min: avoid or use with extreme caution.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50% and monitor; Child-Pugh Class C: contraindicated due to hydrocodone.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50% or extend interval to 24-48 hours. Child-Pugh C: avoid use.
Not recommended in pediatric patients due to risk of respiratory depression; for ages <18, contraindicated.
For edema: 5 mg/kg IV or IM once daily. For glaucoma: 10-15 mg/kg/day IV or IM in divided doses every 6-8 hours.
Initiate with lowest effective dose, monitor for respiratory depression and constipation; maximum 4 tablets per day in patients >65 years.
Initiate at lowest adult dose; monitor renal function and electrolytes; adjust based on creatinine clearance.
Risk of addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion (especially in children) can be fatal; neonatal opioid withdrawal syndrome; cytochrome P450 3A4 interaction (concomitant use with CYP3A4 inhibitors may increase hydrocodone levels); risk of medication errors (confusion between different strengths).
None
Addiction, abuse, and misuse; respiratory depression; neonatal opioid withdrawal syndrome; interactions with CNS depressants; risk of serotonin syndrome with serotonergic drugs; adrenal insufficiency; hypotension; seizures; gastrointestinal obstruction; severe cutaneous reactions (acetaminophen); hepatotoxicity (acetaminophen overdose); acute abdominal conditions; impaired mental/physical abilities; elderly/debilitated patients; renal/hepatic impairment.
Use with caution in patients with hepatic cirrhosis, as acetazolamide can precipitate hepatic encephalopathy due to increased ammonia levels,May cause metabolic acidosis, which can be severe with prolonged use; monitor serum electrolytes and bicarbonate levels,Can precipitate renal calculi due to decreased urinary citrate excretion; ensure adequate hydration,May cause drowsiness, confusion, or ataxia; caution when operating machinery or driving,Use with caution in patients with respiratory acidosis or chronic obstructive pulmonary disease, as metabolic acidosis may worsen respiratory function,Monitor for signs of hypersensitivity reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis,May cause hematologic reactions such as agranulocytosis, aplastic anemia, and thrombocytopenia; monitor blood counts
Significant respiratory depression; acute or severe bronchial asthma (without monitoring or resuscitative equipment); known or suspected gastrointestinal obstruction (including paralytic ileus); hypersensitivity to hydrocodone or acetaminophen; use with MAOIs or within 14 days of such therapy.
Known hypersensitivity to acetazolamide or any sulfonamide-derivative (although cross-reactivity may not occur, caution is advised),Severe hepatic insufficiency or cirrhosis with risk of hepatic encephalopathy,Severe renal impairment (e.g., anuria, glomerular filtration rate <10 m L/min),Metabolic acidosis,Hyponatremia or hypokalemia,Concurrent use with high-dose aspirin (risk of metabolic acidosis and increased salicylate toxicity)
Avoid alcohol due to increased risk of acetaminophen hepatotoxicity and additive CNS depression. Grapefruit juice may increase hydrocodone absorption; consider avoiding. No other significant food interactions.
No specific food interactions reported. However, high-sodium foods may counteract the diuretic effect. Maintain adequate fluid intake to prevent kidney stones. Avoid large amounts of caffeine as it may increase diuresis and electrolyte loss.
FDA Category C. First trimester: Possible increased risk of cardiac defects with oxycodone. Second/third trimester: Chronic use may lead to neonatal opioid withdrawal syndrome; no clear teratogenicity. Acetaminophen is generally safe, but high doses may be hepatotoxic.
Acetazolamide is contraindicated in pregnancy (FDA category C). First trimester: associated with increased risk of neural tube defects and limb anomalies in animal studies; human data limited but suggests potential teratogenicity. Second and third trimesters: may cause fetal metabolic acidosis, electrolyte disturbances, and growth restriction due to carbonic anhydrase inhibition.
Oxycodone: M/P ratio ~0.8-3; present in milk; risk of neonatal sedation. Acetaminophen: M/P ~0.8-1, low risk. Avoid due to oxycodone; consider alternative analgesic.
Acetazolamide is excreted into breast milk in low amounts. M/P ratio is approximately 0.25. Infant exposure is minimal but may cause metabolic acidosis or diuresis. Caution is advised; monitor infant for signs of acidosis or dehydration.
Increased clearance of oxycodone in pregnancy may require increased dose; acetaminophen pharmacokinetics unchanged. Adjust based on pain control and withdrawal risk.
Dose adjustments may be necessary due to increased renal clearance and volume of distribution in pregnancy. Monitor therapeutic effect and adverse reactions; consider starting at lower doses and titrating based on response. No standardized guidelines exist; individualize therapy.
Fixed-dose combination of hydrocodone bitartrate (7.5 mg) and acetaminophen (650 mg). Hydrocodone is a schedule II controlled substance with high abuse potential. Acetaminophen hepatotoxicity risk increases above 3 g/day; prescribe no more than 4 doses per day. Monitor for respiratory depression, especially in opioid-naïve patients. Avoid in severe hepatic impairment. Use with caution in patients with COPD, sleep apnea, or concurrent CNS depressants. Consider naloxone co-prescription if high opioid dose or concurrent benzodiazepine use.
Acetazolamide is a carbonic anhydrase inhibitor used for altitude sickness prophylaxis, glaucoma, and as a diuretic. Monitor for metabolic acidosis, especially in elderly or renal impairment. Can cause hypokalemia; check serum potassium. Contraindicated in hepatic cirrhosis due to risk of hepatic encephalopathy. May cause paresthesias, especially in hands and feet, which are harmless but can be distressing.
Take exactly as prescribed; do not increase dose or frequency.,Do not take with alcohol or other medications containing acetaminophen.,May cause drowsiness or dizziness; avoid driving or operating machinery until effects are known.,Store securely out of reach of children and others; dispose of unused tablets properly.,Seek emergency care for difficulty breathing, severe sedation, or signs of allergic reaction.,Do not abruptly stop after prolonged use; withdrawal symptoms may occur.
Take with food to reduce gastrointestinal upset.,May cause tingling in fingers, toes, or face; this is usually temporary and not harmful.,Drink plenty of fluids unless otherwise instructed to prevent kidney stones.,Avoid alcohol as it may increase side effects like dizziness.,Do not drive or operate machinery until you know how this medication affects you, as it may cause drowsiness or blurred vision.,Report any signs of unusual bleeding, bruising, or signs of infection to your healthcare provider.,Take exactly as prescribed; do not stop suddenly without consulting your doctor.,If used for altitude sickness, start 24-48 hours before ascent and continue for 48 hours at high altitude.
No interactions on record
"Bosutinib, a potent CYP3A4 inhibitor, can significantly increase the serum concentration of acetazolamide, a carbonic anhydrase inhibitor, by reducing its hepatic metabolism. This elevation may potentiate acetazolamide's adverse effects, including metabolic acidosis, electrolyte imbalances (e.g., hypokalemia), and paresthesias, especially in patients with renal impairment. Clinicians should monitor for signs of acetazolamide toxicity when coadministered with bosutinib."
"Acetazolamide, a carbonic anhydrase inhibitor, can cause metabolic acidosis and decrease renal tubular secretion of metformin, potentially increasing metformin plasma concentrations. This combination may elevate the risk of lactic acidosis, a rare but serious adverse effect of metformin. Additionally, acetazolamide-induced hypokalemia can exacerbate metformin-associated hyperlactatemia."
"Acetazolamide, a carbonic anhydrase inhibitor, increases urinary pH and promotes bicarbonate excretion, leading to metabolic alkalosis. This systemic alkalinization enhances renal tubular reabsorption of lithium, paradoxically decreasing lithium clearance and increasing serum lithium concentrations. Clinically, this can precipitate lithium toxicity, manifesting as nausea, tremor, ataxia, or confusion, particularly in patients on stable lithium regimens."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ANEXSIA 7.5/650 vs ACETAZOLAMIDE SODIUM, answered by our medical review team.
ANEXSIA 7.5/650 is a Opioid Analgesic Combination that works by Hydrocodone is a mu-opioid receptor agonist that inhibits ascending pain pathways and alters pain perception; acetaminophen inhibits cyclooxygenase (COX) enzymes, primarily in the CNS, reducing prostaglandin synthesis and fever.. ACETAZOLAMIDE SODIUM is a Carbonic Anhydrase Inhibitor that works by Acetazolamide is a carbonic anhydrase inhibitor. It reversibly inhibits the enzyme carbonic anhydrase, which catalyzes the reversible hydration of carbon dioxide and dehydration of carbonic acid. This results in increased excretion of bicarbonate, sodium, potassium, and water in the urine, leading to metabolic acidosis. Additionally, it reduces aqueous humor secretion in the eye, lowering intraocular pressure, and can decrease cerebrospinal fluid production.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ANEXSIA 7.5/650 and ACETAZOLAMIDE SODIUM depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ANEXSIA 7.5/650 is: 1 tablet orally every 4 to 6 hours as needed; maximum 6 tablets per day.. The standard adult dose of ACETAZOLAMIDE SODIUM is: Adult: 250-500 mg IV or IM every 12-24 hours; for edema, 250-375 mg IV once daily in morning. For glaucoma, 250-1000 mg IV or IM daily in divided doses.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ANEXSIA 7.5/650 and ACETAZOLAMIDE SODIUM in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ANEXSIA 7.5/650 is classified as Category C. FDA Category C. First trimester: Possible increased risk of cardiac defects with oxycodone. Second/third trimester: Chronic use may lead to neonatal opioid withdrawal syndrome; no . ACETAZOLAMIDE SODIUM is classified as Category C. Acetazolamide is contraindicated in pregnancy (FDA category C). First trimester: associated with increased risk of neural tube defects and limb anomalies in animal studies; human d. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.